NATCO Pharma Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de NATCO Pharma de 14.6% y 12% por año respectivamente. Se prevé que el BPA crezca en un 14.4% al año. Se espera que la rentabilidad financiera sea de 20.8% en 3 años.

Información clave

14.6%

Tasa de crecimiento de los beneficios

14.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.8%
Tasa de crecimiento de los ingresos	12.0%
Rentabilidad financiera futura	21.1%
Cobertura de analistas	Good
Última actualización	22 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BSE:524816 - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2026	49,637	17,622	13,478	N/A	10
3/31/2025	45,132	15,273	11,183	N/A	11
3/31/2024	39,185	13,212	6,961	N/A	10
12/31/2023	38,298	12,778	N/A	N/A	N/A
9/30/2023	35,637	11,274	5,230	7,477	N/A
6/30/2023	29,630	8,152	N/A	N/A	N/A
3/31/2023	27,085	7,153	6,435	8,491	N/A
12/31/2022	24,074	3,890	N/A	N/A	N/A
9/30/2022	24,754	4,071	5,575	8,302	N/A
6/30/2022	24,191	4,154	N/A	N/A	N/A
3/31/2022	19,462	1,700	-1,962	465	N/A
12/31/2021	16,833	2,735	N/A	N/A	N/A
9/30/2021	14,780	2,558	-2,457	230	N/A
6/30/2021	18,990	3,931	N/A	N/A	N/A
3/31/2021	20,561	4,409	465	2,988	N/A
12/31/2020	21,756	4,820	N/A	N/A	N/A
9/30/2020	23,026	5,238	1,554	4,466	N/A
6/30/2020	19,861	4,404	N/A	N/A	N/A
3/31/2020	19,150	4,608	587	4,173	N/A
12/31/2019	19,159	4,875	N/A	N/A	N/A
9/30/2019	19,904	5,425	-2,200	1,600	N/A
6/30/2019	20,482	6,060	N/A	N/A	N/A
3/31/2019	20,945	6,444	2,071	6,688	N/A
12/31/2018	24,066	8,235	N/A	N/A	N/A
9/30/2018	24,121	8,815	N/A	N/A	N/A
6/30/2018	22,953	7,838	N/A	N/A	N/A
3/31/2018	21,848	6,962	393	4,636	N/A
12/31/2017	19,817	5,730	N/A	N/A	N/A
9/30/2017	20,895	5,506	N/A	4,985	N/A
6/30/2017	21,679	5,323	N/A	N/A	N/A
3/31/2017	20,202	4,860	N/A	3,458	N/A
12/31/2016	17,697	3,680	N/A	N/A	N/A
9/30/2016	13,692	2,113	N/A	N/A	N/A
6/30/2016	12,431	1,748	N/A	N/A	N/A
3/31/2016	10,423	1,549	N/A	1,122	N/A
12/31/2015	9,355	1,494	N/A	N/A	N/A
9/30/2015	8,549	1,266	N/A	N/A	N/A
6/30/2015	8,390	1,294	N/A	N/A	N/A
3/31/2015	7,305	1,293	N/A	927	N/A
12/31/2014	8,089	1,042	N/A	N/A	N/A
9/30/2014	8,108	1,199	N/A	N/A	N/A
6/30/2014	7,648	1,144	N/A	N/A	N/A
3/31/2014	7,389	1,027	N/A	1,440	N/A
12/31/2013	7,078	900	N/A	N/A	N/A
9/30/2013	6,796	826	N/A	N/A	N/A
6/30/2013	6,906	766	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (14.6% al año) de 524816 es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (14.6% al año) de 524816 crezcan menos que el mercado Indian (17.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 524816 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (12% al año) de 524816 crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12% al año) de 524816 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 524816 sea alta dentro de 3 años (21.1%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

NATCO Pharma Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.9% to ₹895

Price target increased by 9.6% to ₹734

Price target decreased to ₹709

Price target decreased to ₹894

Price target decreased to ₹1,000

Price target increased to ₹1,038

Recent updates

Now 22% undervalued

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹1.25 per share

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Upcoming dividend of ₹0.75 per share

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022

NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022

Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco

Natco Pharma Limited Launches Chlorantraniliprole

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022

NATCO Announces Tentative Approval to Its ANDA for Trabectedin (Generic for Yondelis®)

Upcoming dividend of ₹3.50 per share

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on August 30, 2022

NATCO Pharma Limited to Report Q1, 2023 Results on Aug 09, 2022

NATCO Pharma Limited Announces the Launch of the First Generic Version of Nexavar® (Sorafenib) Tablets in 200 Mg Strength in the U.S. Market

Price target decreased to ₹894

Full year 2022 earnings: EPS and revenues miss analyst expectations

FMC Corporation Files a Suit against NATCO Pharma Limited

NATCO Pharma Limited to Report Q4, 2022 Results on May 30, 2022

Insufficient new directors

NATCO Pharma Limited Announces Executive Changes

NATCO Pharma Limited, Along with Marketing Partner Arrow International Ltd Announces Launch of the First Generic Version of Revlimid®(Lenalidomide Capsules) in 5Mg, 10mg, 15mg, and 25Mg Strengths in the U.S. Market

Executive Vice President of R&D recently bought ₹403k worth of stock

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited Announces Board Changes

NATCO Pharma Limited Receives Approval for the Drug for the Treatment of Covid-19 in India

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Dash Pharmaceuticals LLC for a cash consideration of $18 million.

Price target decreased to ₹1,000

Upcoming dividend of ₹0.50 per share

Second quarter 2022 earnings released: EPS ₹3.57 (vs ₹11.12 in 2Q 2021)

United States District Court for the District of Delaware Issues a Decision Holding Patent Rights of Ibrutinib Tablets Owned by Pharmacyclics LLC Valid and Infringed by Generic Tablet Product from Alvogen Pine Brook LLC and Natco Pharma Ltd

Upcoming dividend of ₹2.00 per share

First quarter 2022 earnings released: EPS ₹4.11 (vs ₹6.74 in 1Q 2021)

Director of FDF recently sold ₹5.4m worth of stock